These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37978187)

  • 1. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
    Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
    Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
    Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
    Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin light chain gene rearrangements display hierarchy in absence of selection for functionality in precursor-B-ALL.
    van der Burg M; Barendregt BH; Szczepañski T; van Wering ER; Langerak AW; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1448-53. PubMed ID: 12145684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
    van der Velden VH; Szczepanski T; Wijkhuijs JM; Hart PG; Hoogeveen PG; Hop WC; van Wering ER; van Dongen JJ
    Leukemia; 2003 Sep; 17(9):1834-44. PubMed ID: 12970784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
    Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
    Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
    Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
    Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of Minimal Residual Disease Detection in Infants With
    Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
    J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Fries C; Burack WR
    Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
    Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq.
    Li Z; Jiang N; Lim EH; Chin WHN; Lu Y; Chiew KH; Kham SKY; Yang W; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
    Leukemia; 2020 Sep; 34(9):2418-2429. PubMed ID: 32099036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
    Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
    Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
    Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
    Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
    Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.